Cargando…
Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)
OBJECTIVE: To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP). DESIGN: Uncontrolled, multicenter, open-label, long-term st...
Autores principales: | Gudin, Jeffrey, Rauck, Richard, Argoff, Charles, Agaiby, Eva, Gimbel, Joseph, Katz, Nathaniel, Doberstein, Stephen K, Tagliaferri, Mary, Tagliaferri, Margit, Potts, Jeffrey, Wild, James, Lu, Lin, Siddhanti, Suresh, Hale, Martin, Markman, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372935/ https://www.ncbi.nlm.nih.gov/pubmed/31361019 http://dx.doi.org/10.1093/pm/pnz169 |
Ejemplares similares
-
SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain
por: Markman, John, et al.
Publicado: (2019) -
Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
por: Henningfield, Jack E, et al.
Publicado: (2020) -
Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018) -
Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018) -
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
por: Webster, Lynn, et al.
Publicado: (2020)